Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: A prospective study

16Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Whole-exome sequencing has shown that lung adenocarcinoma (LAC) can be driven by mutant genes, including TP53, P16, and Smad4. The aim of this study was to clarify protein alterations of P53, P16, and Smad4 and to explore their correlations between the protein alterations and clinical outcome. Methods: We investigated associations among P53 mutant (P53Mut) expression, and P16 and Smad4 loss-of-expression, with clinical outcome in 120 LAC patients who underwent curative resection, using immunohistochemical (IHC) methods. Results: Of the 120 patients, 76 (63.3%) expressed P53Mut protein, whereas 54 (45.0%) loss of P16 expressed and 75 (62.5%) loss of Smad4 expressed. P53Mut expression was associated with tumor size (P = 0.041) and pathological stage (P = 0.025). Loss of P16 expression was associated with lymph node metastasis (P = 0.001) and pathological stage (P < 0.001). Loss of Smad4 expression was associated with tumor size (P = 0.033), lymph node metastasis (P = 0.014), pathological stage (P = 0.017), and tumor differentiation (P = 0.022). Kaplan-Meier survival analysis showed that tumor size (P = 0.031), lymph node metastasis (P < 0.001), pathological stage (P < 0.001), P53Mut protein expression (P = 0.038), and loss of p16 or Smad4 expression (P < 0.001) were significantly associated with shorter overall survival(OS), whereas multivariate analysis indicated that lymph node metastasis (P = 0.014) and loss of p16 or Smad4 expression (P < 0.001) were independent prognostic factors. Analysis of protein combinations showed patients with more alterations had poorer survival (P < 0.001). Spearman correlation analysis showed that loss of Smad4 expression inversely correlated with expression of P53Mut (r = -0.196, P = 0.032) and positively with lost P16 expression (r =0.182, P = 0.047). Conclusions: The findings indicate that IHC status of P53Mut, P16, and Smad4 may predict patient outcomes in LAC.

Cite

CITATION STYLE

APA

Bian, C., Li, Z., Xu, Y., Wang, J., Xu, L., & Shen, H. (2015). Clinical outcome and expression of mutant P53, P16, and Smad4 in lung adenocarcinoma: A prospective study. World Journal of Surgical Oncology, 13(1). https://doi.org/10.1186/s12957-015-0502-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free